Omnicare Raises Dividend, Approves Share Repurchase

Zacks

Omnicare Inc. (OCR) raised its quarterly dividend payment by nearly 43% to 20 cents per share from 14 cents per share. The increased dividend is payable on Dec 24 to shareholders of record as of Dec 16.

OCR believes in a consistent dividend payment policy with raises every year. Last year, the company has raised its dividend by 100% to 14 cents.

Apart from the dividend hike, Omnicare’s board of directors approved the repurchase of additional $500 million shares of its common stock until Dec 31, 2015. This is because the company has completed its previous $350 million repurchase program, authorized on Sep 12, 2012.

Year-to-date, OCR has repurchased 4.2 million shares for $220 million. This has brought the cumulative share repurchase amount to 23.4 million shares at an aggregate cost of $849.7 million since the inception of the program on May 3, 2010.

Following the announcements of dividend hike and share repurchase, OCR hit a new 52-week high of $59.13 on Dec 5. The stock closed at $58.81 on Friday, up 1.0% from a day before.

Omnicare, a Zacks Rank #3 (Hold) stock, posted third-quarter 2013 adjusted earnings per share of 91 cents, surpassing the Zacks Consensus Estimate by a penny as well as the year-ago earnings of 86 cents.

However, the company reported a net loss (including extraordinary and one-time items) of $66.3 million or 65 cents per share, compared with a net profit of $61.4 million or 55 cents in the year-ago period. The downside was mainly on account of a litigation charge of $120 million paid in favor of a voluntary civil settlement.

Net revenues grew 5.3% year over year to $1,581 million in the third quarter, beating the Zacks Consensus Estimate of $1,552 million. Strong gains in the Specialty Care Group (SCG) coupled with continued sales and service efforts in the larger Long-Term Care Group (LTC) helped offset soft results in the hospice pharmacy business (now a part of the LTC Group).

Omnicare narrowed its revenue guidance range for 2013 to $6.2–$6.3 billion from $6.1–$6.3 billion. The Zacks Consensus Estimate for the full year is pegged at $6.3 billion, which coincides with the top end of the guided range.

Adjusted earnings per share are now expected in the range of $3.60 to $3.62 as compared with the earlier guided range of $3.56 to $3.64. The Zacks Consensus Estimate for the full year is pegged at $3.61, which stands at the mid-point of the guided range.

Few better-ranked stocks that are performing well in the medical services industry include Air Methods Corp. (AIRM), BG Medicine, Inc. (BGMD), and Envision Healthcare Holdings, Inc. (EVHC). Air Methods carries a Zacks Rank #1 (Strong Buy), while both BG Medicine and Envision Healthcare carry a Zacks Rank #2 (Buy).

Read the Full Research Report on OCR
Read the Full Research Report on BGMD
Read the Full Research Report on AIRM
Read the Full Research Report on EVHC


Zacks Investment Research

View Comments (0)